Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stuart Dowall has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defining Challenge Conditions for Nipah Virus in the Syrian Golden Hamster Model: Effects of Dose, Exposure Route and Viral Strain

    by Emma Kennedy, Stephen Findlay-Wilson, Francisco J. Salguero, Ines Ruedas-Torres, Susan Fotheringham, Linda Easterbrook, Victoria A. Graham, Sarah Kempster, Neil Almond, Stuart D. Dowall

    Nipah virus (NiV) is a highly pathogenic zoonotic virus for which no licensed vaccines or therapeutics are currently available, necessitating well-characterised animal models to support countermeasure development. This study aimed to establish an appropriate challenge dose in the Syrian golden hamster model at the UK Health Security Agency (UKHSA), incorporating both intraperitoneal (i.p.) and intranasal (i.n.) routes of infection and two clinically relevant strains, NiV-Malaysia (NiV-M) and NiV-Bangladesh (NiV-B). Due to a different challenge doses and susceptibilities of hamsters to NiV being reported in the literature, there is a prerequisite to define the model parameters upon establishment in a new facility. Dose-ranging studies were performed across multiple independent experiments assessing survival, clinical progression and histopathological outcomes. Challenge via the i.p. route produced consistent and severe disease using an infectious dose of 103 TCID50 for both strains. In contrast, animals were more susceptible to infection via i.n. challenge with a dose of 10 TCID50 resulting in uniform lethality. For both challenge routes, respiratory and neurological disease manifestations were observed. These distinct disease phenotypes were supported by histopathological findings and viral RNA distribution in affected organs. Differences between strains were evident, with NiV-B showing a tendency towards a broader pulmonary pathology at lower doses after i.n. challenge. Collectively, these findings demonstrate that challenge dose, route of exposure, and viral strain influence disease outcomes in the hamster model.

  • Open Access

    Protective titre of the WHO international standard for anti-chikungunya virus antibodies in a mouse model

    by Stuart D. Dowall, Stephen Findlay-Wilson, Victoria A. Graham, Daniel A. Yara, Amelia Warren, Linda Easterbrook, Jack Smith, Emma Kennedy, Francisco J. Salguero, Ines Ruedas-Torres, et al.

  • Open Access

    Preclinical Models of Oropouche Virus Infection and Disease

    by Daniel Morley, Emma Kennedy, Stuart Dowall

    Oropouche virus (OROV) is an emerging and underreported arbovirus with dengue-like symptoms confounding diagnosis. OROV is also neuroinvasive, with a small number of cases presenting severe neurological symptoms. There have been recently reported deaths from confirmed cases of OROV and reported instances of vertical transmission from mother to foetus, with confirmed cases in Brazil and a congenital anomaly, reportedly as a consequence of OROV infection in Cuba, with further cases under investigation. Whilst cases of OROV infection occur mainly in South America, many cases have been imported elsewhere, including the United States and Europe. Despite the emerging threat to public health, animal modelling to study OROV pathogenicity and immunity and to evaluate therapeutic candidates remains limited. For this review, we carried out a literature search through major research databases (PubMed and Scopus) up to September 2025 to capture the extent of in vivo model development for this pathogen. We identified only 17 relevant primary research articles within these criteria which detailed hamster, mouse and non-human primate (NHP) models. Here, we discuss the extent of in vivo model development for OROV. In summary, small and large animal models need to be assessed with recent clinical isolates and reassortants, asymptomatic disease presentation in the NHP model requires further study and the hamster model shows potential for use in pathogenicity and vaccine or antiviral efficacy studies. We also compile relevant metadata and discuss the need for an animal model that more closely resembles human disease.


  • Open Access

    Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine

    by Martina Pfranger, Nina Krause, Benedikt Asbach, Johannes Meier, George Carnell, Lara Scheer, Anja Kalender, David Brenner, Paul Tonks, Simon Frost, et al.

    A multivalent vaccine targeting high-consequence infectious diseases in Sub-Saharan Africa (SSA), which are linked to high mortality, morbidity and overlapping clinical manifestations, would significantly improve health security and economic stability in this region. Trivalent vector vaccines were devised to deliver digitally optimized versions of Orthoebolavirus, Orthomarburgvirus glycoproteins (GPs) and a Lassa mammarenavirus (LASV) nucleoprotein (NP) by a single Modified Vaccinia Ankara (MVA) known to protect against mpox virus (MPXV) along with a matched DNA vaccine. Three immunizations in mice and Hartley guinea pigs with MVA only or a DNA prime followed by two MVA administrations induced comparable levels of binding antibodies and LASV-specific T-cells, respectively. While DNA priming mitigated MVA-specific antibody responses, GP- and NP-specific antibodies developed already after a single MVA vaccination. Although a post-outbreak Ebola virus vaccine is available, outbreaks by other filoviruses, annual LASV epidemics and increased incidence of MPXV infections support the rationale for an MVA-based trivalent haemorrhagic fever vaccine for endemic and high-risk human populations in SSA.


  • Open Access

    Susceptibility and transmission of mpox virus infection in brown rats (Rattus norvegicus)

    by Lucy Crossley, Stephen Findlay-Wilson, Linda Easterbrook, Emma Kennedy, Francisco J. Salguero, Kim Mackay, Victoria Graham, Susan Fotheringham, Stuart Dowall

    A corrigendum of this article has been published full details can be found at https://doi.org/10.1099/jgv.0.002162 . Mpox (formerly known as monkeypox) virus (MPXV) is the zoonotic pathogen of mpox disease in humans. Its increasing emergence outside of its endemic area has heightened the importance of investigating the virus’ prevalence and maintenance in sylvatic reservoirs. The common brown rat (Rattus norvegicus) can inhabit almost anywhere in the UK, posing a threat to zoonotic transmission to humans. Two independent studies were carried out; the first investigated the susceptibility of brown rats to MPXV infection with a clade IIb mpox strain via two challenge routes: intranasal and intradermal. The second study considered the transmission of MPXV between challenged and naïve brown rats. All animals were asymptomatic to mpox disease, although enzyme-linked immunosorbent assay (ELISA) confirmed subclinical infection in challenge groups. In the susceptibility study, reverse transcription PCR (RT-PCR) detected mpox DNA in the lung tissue and throat swabs within the intranasally inoculated group, in addition to viable virus observed from the intranasal throat swabs. In contrast, no virus was detected in either tissues or swabs in the intradermally inoculated group or control group. RT-PCR results from the transmission study detected mpox DNA in tissues and throat swabs taken from challenged animals. Viable virus was observed from tissues and swabs of intranasally challenged animals with infectious titres of ~102–104 TCID50 per millilitre. ELISA assays in the transmission study showed replicable results compared to the first susceptibility study in directly challenged animals alongside evidence of seroconversion in co-housed naïve animals. In conclusion, brown rats are susceptible to MPXV infection, as they have been demonstrated to maintain viable virus in the absence of clinical signs. Viral transmission of MPXV from infected rats to naïve rats was not observed by RT-PCR, although naïve rats did show antibody responses when exposed to infected rats indicating exposure to virus.


  • Open Access

    Genomic changes of Lassa virus associated with mammalian host adaptation

    by Linda Easterbrook, Xiaofeng Dong, Jack Smith, Susan Fotheringham, Sarah Kempster, Catherine Hartley, Tessa Prince, Victoria Graham, Emma Kennedy, Stephen Findlay-Wilson, et al.

    Background: Lassa virus (LASV) causes a severe haemorrhagic fever in humans, with estimates of 100,000 to 300,000 infections annually in endemic regions and accounting for around 5000 deaths. The natural reservoir is the Mastomys rat, but through zoonotic transmissions humans are accidental hosts. Regular outbreaks continue to exert pressures on public health systems, with its ability to cause nosocomial infections posing risks to healthcare workers. It is a concern that larger outbreaks and introduction of LASV to new territories will intensify, including risk of adaptation to new mammalian host reservoirs. Results: To evaluate genetic changes in LASV during adaptation to a new host, a guinea pig model of infection was utilised. Initial infection with LASV stocks cultured from cell culture resulted in only mild or subclinical disease. To study the susceptibility in naïve animals, the virus was serially passaged which increased clinical signs during disease progression ultimately resulting in severe disease. An RNAseq and consensus mapping approach was undertaken to evaluate nucleotide changes in LASV genome from each animal at each passage. Conclusions: During adaptation to guinea pigs, no significant new mutations occurred. Instead, a selection pressure on two genes of the L segment was observed resulting in their increased frequency in the genome population during passaging.

  • Open Access

    A Multi-Valent Hantavirus Vaccine Based on Recombinant Modified Vaccinia Ankara Reduces Viral Load in a Mouse Infection Model

    by Marilyn Aram, Victoria Graham, Emma Kennedy, Emma Rayner, Roger Hewson, Stuart Dowall

    Background: Old World orthohantaviruses are the aetiological agent of Haemorrhagic Fever with Renal Syndrome (HFRS) disease. Worldwide, the two most prominent pathogens of HFRS are Seoul orthohantavirus (SEOV) and Hantaan orthohantavirus (HTNV). There is currently no specific treatment nor widely licensed vaccine form hantaviruses. Methods: This study developed a virus-vectored vaccine approach using modified vaccinia Ankara (MVA) incorporating a SEOV-HTNV chimeric nucleoprotein antigen. Results: The vaccine demonstrated the induction of humoral and cellular immunity. In the absence of a disease model, a reduction in the viral load of a susceptible mouse strain with type-I interferon receptor deficiency (A129) was used to ascertain protective effects after challenge with SEOV. Results demonstrated a significant reduction in and/or clearance of viral RNA in immunised animals. Conclusions: An MVA viral vector vaccine incorporating the nucleoprotein as antigen offers a promising approach for Hantavirus vaccine development.


  • Open Access

    Cross-protectivity of henipavirus soluble glycoprotein in an in vivo model of Nipah virus disease

    by Stephen Findlay-Wilson, Nazia Thakur, Lucy Crossley, Linda Easterbrook, Francisco J. Salguero, Ines Ruedas-Torres, Susan Fotheringham, Emma Kennedy, Dalan Bailey, Stuart Dowall

    Introduction: Nipah virus (NiV) is one of a group of highly pathogenic viruses classified within the Henipavirus genus. Since 2012 at least 11 new henipa-like viruses have been identified, including from new locations and reservoir hosts; the pathogenicity of these new viruses has yet to be determined, but two of them have been associated with morbidity, including fatalities.Methods: The efficacy and cross-reactivity of two vaccine candidates derived from the soluble glycoproteins of both NiV and Hendra virus (HeV) was evaluated in our recently established hamster model.Results: Both vaccine preparations resulted in strong humoral responses against NiV antigenic targets, demonstrating cross-reactive immunity. Efficacy was determined through challenge of hamsters with NiV Malaysian (NiV-M) strain. 100% of the hamsters survived a lethal challenge dose after prime/boost immunisation with glycoproteins derived from both NiV and HeV in the presence of adjuvant, with clinical signs and pathology being significantly reduced in immunised animals.Discussion: This is first time the NiV and HeV soluble glycoproteins have been compared in the NiV-M hamster challenge model in the presence of Alhydrogel and AddaVax, providing evidence that glycoproteins from closely related henipavirus species can provide cross-protectivity against infection from alternate henipaviruses, supporting the potential of an effective pan-henipavirus vaccine for use in a frontline outbreak response.


  • Open Access

    Attenuation of Chikungunya Virus by a Single Amino Acid Substitution in the nsP1 Component of a Non-Structural Polyprotein

    by John Chamberlain, Stuart D. Dowall, Jack Smith, Geoff Pearson, Victoria Graham, John Raynes, Roger Hewson

    Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that, since its re-emergence in 2004, has become recognised as a major public health concern throughout many tropical and sub-tropical regions of the world. Amongst the insights gained from studies on other alphaviruses, several key determinants of virulence have been identified, including one present at the P3 position in the nsP1/nsP2 cleavage domain of the S.A.AR86 Sindbis (SINV) strain. This strain is associated with neurovirulence in adult mice; however, when a threonine-to-isoleucine substitution is engineered at this P3 position, an attenuated phenotype results. A reverse genetics system was developed to evaluate the phenotype that resulted from the substitution of alanine, present at the P3 position in the wild-type CHIKV clone, with valine. The A533V-mutant CHIKV induced milder disease symptoms in the C57BL/6 mouse model than the wild-type virus, in terms of severity of inflammation, length of viraemic period, and histological changes. Furthermore, the induction of type I IFN occurred more rapidly in both CHIKV-infected cell cultures and the mouse model with the mutant CHIKV.


  • Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine

    by Emma Kennedy, Roger Hewson, Stuart Dowall

    One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.